Agios Pharmaceuticals bagged $78 million in an oversubscribed Series C, signaling that the financing gate – if not floodgate – remains open for emerging biotechs. Read More
With drug prices continuing their upward climb, several senators are launching bipartisan efforts to shoot them down with increased competition. And that's putting pay-for-delay settlements at the center of congressional crosshairs. Read More
Women suffering from recurrent urinary tract infections (UTI) may soon finally be able to limit the cranberry juice to Thanksgiving. Scientists have described a series of compounds this week that, in animal studies, fight the bacterium that is behind 85 percent to 90 percent of UTIs. Read More
LONDON – Oxyrane Ltd. has raised $26.5 million in a fourth private round as it prepares to move its first enzyme replacement therapy into clinical development for the treatment of Pompe's disease. Read More
• Inovio Pharmaceuticals Inc., of Blue Bell, Pa., said a single intradermal electroporation boost of its SynCon avian influenza vaccine generated hemagglutination inhibition (HAI) titers against six different unmatched strains of H5N1, and it generated a fourfold or greater rise in HAI titers in 50 percent of boosted subjects in a Phase I study. Read More
• Avanir Pharmaceuticals Inc., of Aliso Viejo, Calif., said the European Medicines Agency accepted the marketing authorization application filing for Nuedexta (dextromethorphan HBr and quinidine sulfate) to treat pseudobulbar affect. Nuedexta gained approval in the U.S. in October 2010. Read More
